Jefferies Comments On Covance On 2Q

According to Jefferies, Covance CVD $60 PT is based on 18.5x the 2012 EPS estimate of $3.24, which is a slight premium to the rest of the group. Jefferies said that its 2012 estimate moves slightly below consensus. CVD continues to command a premium, but valuation at this level is mildly stretched. “Risks: 1) failed recovery in ED, 2) slower backlog conversion and/or cancellations, 3) decline in late-stage margin like that experienced in Early over the last three years.” Covance closed yesterday at $57.68.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorAnalyst RatingsHealth CareJefferiesLife Sciences Tools & Services
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!